Image pharmaphorum Editor News Roche haemophilia data piles pressure on Shire Hemlibra threatens to take market share from Advate News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering White Papers Sponsored Medical meetings and what HCPs want The healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the digital age new research has shown that face-to-face meetings retain a prominent place News FDA approves Pfizer's epoetin biosimilar Retacrit Epoetin alfa biosimilars available in EU for more than a decade Load more results
News Roche haemophilia data piles pressure on Shire Hemlibra threatens to take market share from Advate
News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering
White Papers Sponsored Medical meetings and what HCPs want The healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the digital age new research has shown that face-to-face meetings retain a prominent place
News FDA approves Pfizer's epoetin biosimilar Retacrit Epoetin alfa biosimilars available in EU for more than a decade
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
